Literature DB >> 24958229

Decreased serum TNF-alpha levels in chronic schizophrenia patients on long-term antipsychotics: correlation with psychopathology and cognition.

Meng Han Lv1, Yun Long Tan, Shao Xiao Yan, Li Tian, Da Chun Chen, Shu Ping Tan, Zhi Ren Wang, Fu De Yang, Jin H Yoon, Giovana B Zunta-Soares, Jair C Soares, Xiang Yang Zhang.   

Abstract

OBJECTIVE: A substantial body of evidence implicates TNF-alpha (TNFα) and TNFα-related signaling pathways in the pathophysiology of schizophrenia. The current study examined the relationship between TNFα serum levels and both psychopathological as well as cognitive symptoms in schizophrenia.
MATERIALS AND METHODS: Serum TNFα levels were assessed in 89 patients diagnosed with schizophrenia and compared to 43 healthy control subjects matched for age and gender. Schizophrenic symptomatology was assessed with the Positive and Negative Syndrome Scale (PANSS), and serum TNFα levels were measured by sandwich enzyme-linked immunosorbent assay (ELISA).
RESULTS: TNFα levels were significantly lower in patients with chronic schizophrenia relative to healthy control subjects (p<0.01). Correlation analysis revealed a significant negative correlation between the TNFα levels and the PANSS total score (p<0.01). Additionally, TNFα levels were significantly negatively correlated with scores on general psychopathology (p<0.01), positive (p<0.05) and cognitive subscales (p<0.05). Stepwise multiple regression analysis identified TNFα levels as a significant predictor of scores on the general psychopathology subscale of the PANSS.
CONCLUSION: The significant relations observed in the current study between TNFα and the PANSS and its subscales suggest that immune disturbance may be involved in the psychopathology and cognitive deficits of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24958229     DOI: 10.1007/s00213-014-3650-y

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  57 in total

Review 1.  Cytokines and the brain: implications for clinical psychiatry.

Authors:  Z Kronfol; D G Remick
Journal:  Am J Psychiatry       Date:  2000-05       Impact factor: 18.112

2.  Efficacy of iloperidone in schizophrenia: a PANSS five-factor analysis.

Authors:  Leslie Citrome; Xiangyi Meng; Marla Hochfeld
Journal:  Schizophr Res       Date:  2011-06-22       Impact factor: 4.939

Review 3.  Tumor necrosis factor alpha, interleukin-1 beta, interleukin-6 and major histocompatibility complex molecules in the normal brain and after peripheral immune challenge.

Authors:  Leonardo H Tonelli; Teodor T Postolache
Journal:  Neurol Res       Date:  2005-10       Impact factor: 2.448

4.  Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review.

Authors:  Stéphane Potvin; Emmanuel Stip; Amir A Sepehry; Alain Gendron; Ramatoulaye Bah; Edouard Kouassi
Journal:  Biol Psychiatry       Date:  2007-11-19       Impact factor: 13.382

5.  Tumor necrosis factor promoter haplotype associated with schizophrenia reveals a linked locus on 1q44.

Authors:  V Saviouk; E W C Chow; A S Bassett; L M Brzustowicz
Journal:  Mol Psychiatry       Date:  2005-04       Impact factor: 15.992

6.  Five factor model of schizophrenia: replication across samples.

Authors:  J P Lindenmayer; S Grochowski; R B Hyman
Journal:  Schizophr Res       Date:  1995-02       Impact factor: 4.939

Review 7.  Role of immunological factors in the pathophysiology and diagnosis of bipolar disorder: comparison with schizophrenia.

Authors:  A Carlo Altamura; Massimiliano Buoli; Sara Pozzoli
Journal:  Psychiatry Clin Neurosci       Date:  2013-09-19       Impact factor: 5.188

Review 8.  The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia.

Authors:  Kyoung-Sae Na; Han-Yong Jung; Yong-Ku Kim
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-11-01       Impact factor: 5.067

9.  Changes of plasma concentrations of interleukin-1 alpha and interleukin-6 with neuroleptic treatment for schizophrenia.

Authors:  H M Xu; J Wei; G P Hemmings
Journal:  Br J Psychiatry       Date:  1994-02       Impact factor: 9.319

10.  Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia.

Authors:  Xiang Yang Zhang; Dong Feng Zhou; Lian Yuan Cao; Pei Yan Zhang; Gui Ying Wu; Yu Cun Shen
Journal:  J Clin Psychiatry       Date:  2004-07       Impact factor: 4.384

View more
  19 in total

1.  Inflammation in individuals with schizophrenia - Implications for neurocognition and daily function.

Authors:  Sophia Kogan; Luz H Ospina; David Kimhy
Journal:  Brain Behav Immun       Date:  2018-09-12       Impact factor: 7.217

2.  Inflammation in Schizophrenia: Cytokine Levels and Their Relationships to Demographic and Clinical Variables.

Authors:  Ellen E Lee; Suzi Hong; Averria Sirkin Martin; Lisa T Eyler; Dilip V Jeste
Journal:  Am J Geriatr Psychiatry       Date:  2016-10-17       Impact factor: 4.105

Review 3.  Bridging Autism Spectrum Disorders and Schizophrenia through inflammation and biomarkers - pre-clinical and clinical investigations.

Authors:  Joana Prata; Susana G Santos; Maria Inês Almeida; Rui Coelho; Mário A Barbosa
Journal:  J Neuroinflammation       Date:  2017-09-04       Impact factor: 8.322

4.  Immuno-metabolic profile of patients with psychotic disorders and metabolic syndrome. Results from the FACE-SZ cohort.

Authors:  Marianne Foiselle; Susana Barbosa; Ophélia Godin; Ching-Lien Wu; Wahid Boukouaci; Myrtille Andre; Bruno Aouizerate; Fabrice Berna; Caroline Barau; Delphine Capdevielle; Pierre Vidailhet; Isabelle Chereau; Laetitia Davidovic; Jean-Michel Dorey; Caroline Dubertret; Julien Dubreucq; Catherine Faget; Guillaume Fond; Sylvain Leigner; Pierre-Michel Llorca; Jasmina Mallet; David Misdrahi; Emanuela Martinuzzi; Christine Passerieux; Romain Rey; Baptiste Pignon; Mathieu Urbach; Franck Schürhoff; Nicolas Glaichenhaus; Marion Leboyer; Ryad Tamouza
Journal:  Brain Behav Immun Health       Date:  2022-03-29

5.  Integrated Post-GWAS Analysis Sheds New Light on the Disease Mechanisms of Schizophrenia.

Authors:  Jhih-Rong Lin; Ying Cai; Quanwei Zhang; Wen Zhang; Rubén Nogales-Cadenas; Zhengdong D Zhang
Journal:  Genetics       Date:  2016-10-17       Impact factor: 4.562

6.  Relationship of serum levels of TNF-α, IL-6 and IL-18 and schizophrenia-like symptoms in chronic ketamine abusers.

Authors:  Ni Fan; Yayan Luo; Ke Xu; Minling Zhang; Xiaoyin Ke; Xini Huang; Yi Ding; Daping Wang; Yuping Ning; Xuefeng Deng; Hongbo He
Journal:  Schizophr Res       Date:  2015-11-14       Impact factor: 4.939

7.  Sex differences in TGFB-β signaling with respect to age of onset and cognitive functioning in schizophrenia.

Authors:  Dorota Frydecka; Błażej Misiak; Edyta Pawlak-Adamska; Lidia Karabon; Anna Tomkiewicz; Paweł Sedlaczek; Andrzej Kiejna; Jan Aleksander Beszłej
Journal:  Neuropsychiatr Dis Treat       Date:  2015-03-05       Impact factor: 2.570

8.  Effects of Ketamine on Levels of Inflammatory Cytokines IL-6, IL-1β, and TNF-α in the Hippocampus of Mice Following Acute or Chronic Administration.

Authors:  Yanning Li; Ruipeng Shen; Gehua Wen; Runtao Ding; Ao Du; Jichuan Zhou; Zhibin Dong; Xinghua Ren; Hui Yao; Rui Zhao; Guohua Zhang; Yan Lu; Xu Wu
Journal:  Front Pharmacol       Date:  2017-03-20       Impact factor: 5.810

9.  Tumor necrosis factor-α and -β genetic polymorphisms as a risk factor in Saudi patients with schizophrenia.

Authors:  Saeed Kadasah; Misbahul Arfin; Sadaf Rizvi; Mohammed Al-Asmari; Abdulrahman Al-Asmari
Journal:  Neuropsychiatr Dis Treat       Date:  2017-04-12       Impact factor: 2.570

10.  Nucks1 gene polymorphism rs823114 is associated with the positive symptoms and neurocognitive function of patients with schizophrenia in parts of southern China.

Authors:  Xia Wen; Xusan Xu; Xudong Luo; Jinwen Yin; Chunmei Liang; Jinyuan Zhu; Xueyan Nong; Xiudeng Zhu; Fan Ning; Shanshan Gu; Susu Xiong; Jiawu Fu; Dongjian Zhu; Zhun Dai; Dong Lv; Zhixiong Lin; Juda Lin; You Li; Guoda Ma; Yajun Wang
Journal:  Psychiatr Genet       Date:  2021-08-01       Impact factor: 2.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.